Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.
Host-defense piscidin peptides as antibiotic adjuvants against Clostridioides difficile.
复制标题
DOI:
10.1371/journal.pone.0295627
复制
发表时间:
2024
期刊:
影响因子:
3.7
通讯作者:
中科院分区:
文献类型:
--
作者:
The spore-forming intestinal pathogen Clostridioides difficile causes multidrug resistant infection with a high rate of recurrence after treatment. Piscidins 1 (p1) and 3 (p3), cationic host defense peptides with micromolar cytotoxicity against C. difficile, sensitize C. difficile to clinically relevant antibiotics tested at sublethal concentrations. Both peptides bind to Cu2+ using an amino terminal copper and nickel binding motif. Here, we investigate the two peptides in the apo and holo states as antibiotic adjuvants against an epidemic strain of C. difficile. We find that the presence of the peptides leads to lower doses of metronidazole, vancomycin, and fidaxomicin to kill C. difficile. The activity of metronidazole, which targets DNA, is enhanced by a factor of 32 when combined with p3, previously shown to bind and condense DNA. Conversely, the activity of vancomycin, which acts at bacterial cell walls, is enhanced 64-fold when combined with membrane-active p1-Cu2+. As shown through microscopy monitoring the permeabilization of membranes of C. difficile cells and vesicle mimics of their membranes, the adjuvant effect of p1 and p3 in the apo and holo states is consistent with a mechanism of action where the peptides enable greater antibiotic penetration through the cell membrane to increase their bioavailability. The variations in effects obtained with the different forms of the peptides reveal that while all piscidins generally sensitize C. difficile to antibiotics, co-treatments can be optimized in accordance with the underlying mechanism of action of the peptides and antibiotics. Overall, this study highlights the potential of antimicrobial peptides as antibiotic adjuvants to increase the lethality of currently approved antibiotic dosages, reducing the risk of incomplete treatments and ensuing drug resistance.
登录
查看更多内容
影响因子:
4.9
作者:
Deshpande, Aditi;Wu, Xiaoqian;Hurdle, Julian G.
通讯作者:
Hurdle, Julian G.
DOI:
10.1126/science.aad3292
发表时间:
2016-01-01
期刊:
Science (New York, N.Y.)
影响因子:
--
作者:
Baym M;Stone LK;Kishony R
通讯作者:
Kishony R
影响因子:
--
作者:
Duong L;Gross SP;Siryaporn A
通讯作者:
Siryaporn A
影响因子:
2.4
作者:
Feuerstadt, Paul;Stong, Laura;Nelson, Winnie W.
通讯作者:
Nelson, Winnie W.
DOI:
10.1073/pnas.0306859101
发表时间:
2004-05-18
影响因子:
11.1
作者:
Cowan, AE;Olivastro, EM;Setlow, P
通讯作者:
Setlow, P